Live Breaking News & Updates on Golimumab simponi

Stay informed with the latest breaking news from Golimumab simponi on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Golimumab simponi and stay connected to the pulse of your community

Inflammatory Bowel Diseases (IBD) Drugs Market Is Projected To Grow At A CAGR 6.2% By 2034: Visiongain

Inflammatory Bowel Diseases (IBD) Drugs Market Is Projected To Grow At A CAGR 6.2% By 2034: Visiongain
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

China , India , Vedolizumab-entyvio , Ustekinumab-stelara , Adalimumab-humira , Golimumab-simponi , Infliximab-remicade , Johnsons , European-union , Analysis-of-leading-companies , National-market-analysis , Pfizer-inc

Psoriasis Treatment & Drug Market Insights: A Guide for New & Existing Entrants, Price and Reimbursement, Pipeline Assessment, and Epidemiology Study

/PRNewswire/ -- Psoriasis is a chronic skin condition that causes cells to build up rapidly on the skin's surface. This leads to the formation of thick, red...

London , City-of , United-kingdom , United-states , Etanercept-enbrel , Vishal-sawant , Infliximab-remicade , Golimumab-simponi , Adalimumab-humira , Advancements-in-psoriasis-therapy-research , Ai-healthcare-solutions , Our-services

Brandessence Market Research and Consulting Private Limited: Psoriasis Treatment & Drug Market Insights: A Guide for New & Existing Entrants, Price and Reimbursement, Pipeline Assessment, and Epidemiology Study

Brandessence Market Research and Consulting Private Limited: Psoriasis Treatment & Drug Market Insights: A Guide for New & Existing Entrants, Price and Reimbursement, Pipeline Assessment, and Epidemiology Study
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

London , City-of , United-kingdom , Steigen , Baden-wüberg , Germany , United-states , Vishal-sawant , Golimumab-simponi , Adalimumab-humira , Infliximab-remicade , Etanercept-enbrel

Cipla partners with Alvotech to market biosimilars in Australia and New Zealand

Cipla announced that its subsidiary, Cipla Gulf FZ LCC (Cipla Gulf) is expanding its partnership with Alvotech for the marketing and distribution of four biosimilar medicines in Australia and New Zealand.
As part of this strategic alliance, Cipla Gulf will be responsible for commercialization of
patented biosimilars of the biologic medicine brands, Aflibercept (Eylea), Ustekimumab
(Stelara), Denosumab (Prolia, Xgeva) and Golimumab (Simponi). These are leading
products covering therapeutic categories across immunology, osteoporosis, oncology
as well as ophthalmology (eg.
Aflibercept is indicated for nAMD and other serious eye
diseases).
The products are developed and manufactured by Alvotech and will be distributed by

Australia , New-zealand , Aflibercept-eylea , Ustekimumab-stelara , Golimumab-simponi , Cipla , Cipla-gulf , Capital-market , Nifty-50 , Life-sciences , Biosimilar , Industry-economics

Ulcerative Colitis Market Scenario 2020 – Current Trends, Size, Share and Future Opportunities by 20

Ulcerative Colitis Market Scenario 2020 – Current Trends, Size, Share and Future Opportunities by 2026
Global Ulcerative Colitis Market – Insights
Ulcerative colitis (UC), also known as colitis ulcerosa, is a chronic, inflammatory bowel disease that causes inflammation in the digestive tract. It is characterized by diarrhea, sudden and unexplained weight loss, loss of appetite, belly pain/cramps, bleeding from the rectum, joint pain, eye disease, thickening of the intestinal wall, blood infection (sepsis), kidney stones, and liver disease. The inflammation results in development of tiny sores known as ulcers. Although the exact cause for UC is not known, probable factors include, genetic aspects, environmental changes, or weakened immune system. Healthy diet, proper hydration, skipping fatty foods, and limited consumption of high-fiber food can help to prevent UC. Although the incidence of the disease is high among people under 30 years of age, it may impact people of any age.

Japan , United-states , India , United-kingdom , America , Olsalazine-dipentum , Adalimumab-humira , Sulfasalazine-azulfidine , Infliximab-remicade , Vedolizumab-entyvio , Mesalamine-asacol , Asia-pacific

Cipla secures USFDA nod on Sumatriptan nasal spray

The drug major has received final approval for its Abbreviated New Drug Application (ANDA) for Sumatriptan nasal spray, 20 mg from the United States Food and Drug Administration (USFDA).
The product is an AB-rated generic therapeutic equivalent version of GlaxoSmithKline's Imitrex nasal spray. Imitrex is a serotonin (5-HT1B/1D) receptor agonist (triptan) indicated for acute treatment of migraine with or without aura in adults.
According to IQVIA (IMS Health), Imitrex nasal spray 20 mg and its generic equivalents had US sales of approximately $53.3 million for the 12-month period ending December 2020.
Separately, Cipla announced that its subsidiary, Cipla Gulf FZ LCC, is expanding its partnership with Alvotech for the marketing and distribution of four biosimilar medicines in Australia and New Zealand.

South-africa , Australia , United-states , New-zealand , India , America , Aflibercept-eylea , Ustekimumab-stelara , Glaxosmithkline-imitrex , Golimumab-simponi , Drug-administration , Cipla

Cipla Gulf Expands Partnership with Alvotech for Commercialization of Biosimilars in Australia and New Zealand

Cipla Gulf Expands Partnership with Alvotech for Commercialization of Biosimilars in Australia and New Zealand

Australia , Arizona , United-states , New-zealand , Nishant-saxena , Aflibercept-eylea , Ustekimumab-stelara , Golimumab-simponi , International-business-europe-emerging , Cipla , Cipla-limited , Cipla-gulf-expands-partnership

Kamux's CEO Juha Kalliokoski assigns Kamux's shares in his possession to his children

Kamux's CEO Juha Kalliokoski assigns Kamux's shares in his possession to his children
globalbankingandfinance.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globalbankingandfinance.com Daily Mail and Mail on Sunday newspapers.

South-africa , Australia , United-states , New-zealand , Mumbai , Maharashtra , India , America , Nishant-saxena , Aflibercept-eylea , Ustekimumab-stelara , Golimumab-simponi

Cipla expands Alvotech partnership to market four more biosimilars in Australia and New Zealand

Cipla expands Alvotech partnership to market four more biosimilars in Australia and New Zealand
thehindubusinessline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindubusinessline.com Daily Mail and Mail on Sunday newspapers.

Australia , New-zealand , Mumbai , Maharashtra , India , Aflibercept-eylea , Ustekimumab-stelara , Golimumab-simponi , Cipla , Drug-maker-cipla , Cipla-gulf , Abbreviated-new-drug-application